Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ortho_Tri-Cyclen
gptkb:Schering-Plough |
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:brand |
gptkb:Nuva_Ring
|
| gptkbp:clinical_trial |
conducted for safety
conducted for efficacy |
| gptkbp:contraindication |
certain cancers
history of blood clots smoking over age 35 |
| gptkbp:demographics |
women of reproductive age
|
| gptkbp:duration |
one month
|
| gptkbp:education |
informed about side effects
advised on missed doses instructed on proper use |
| gptkbp:frequency |
once a month
after three weeks |
| https://www.w3.org/2000/01/rdf-schema#label |
Nuva Ring
|
| gptkbp:ingredients |
gptkb:ethinyl_estradiol
etonogestrel |
| gptkbp:interacts_with |
antibiotics
anticonvulsants HIV medications |
| gptkbp:is_effective_against |
over 99% with perfect use
91% with typical use |
| gptkbp:manager |
vaginal
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketed_as |
contraceptive ring
|
| gptkbp:packaging |
single-use ring
|
| gptkbp:products |
gptkb:spacecraft
injection IUD |
| gptkbp:regulatory_compliance |
prescription only
|
| gptkbp:release_region |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:replaced_by |
birth control pills
|
| gptkbp:reproduction |
immediate after removal
|
| gptkbp:research_focus |
user satisfaction
long-term effects comparative effectiveness |
| gptkbp:side_effect |
gptkb:historical_event
heart attack headache nausea stroke hypertension weight gain breast tenderness mood changes thromboembolism menstrual changes gallbladder disease vaginal discharge vaginal irritation |
| gptkbp:storage |
room temperature
|
| gptkbp:type |
gptkb:drug
|
| gptkbp:uses |
prevent pregnancy
|